


We claim:

1. A compound of the Formula 1:



Formula 1

wherein;

R₁ is selected from the group consisting of aryl, heteroaryl, cycloalkyl and heterocycloalkyl;

wherein R₁ is optionally substituted with one or more substituents R_a;

wherein R_a is selected from the group consisting of alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro, aryl, heteroaryl, aralkyl, heteroaralkyl and -(R₇)_nNR₈R₉

wherein R₇ is selected from alkyl, alkoxy, and oxyalkyl, R₈ and R₉ can be independently selected from H, and alkyl, or R₈ and R₉ can join together such that NR₈R₉ form a 5 or 6-member heterocyclic ring, and *n* is selected from 0, 1, 2 and 3)

wherein the substituent(s) R_a is optionally further substituted with one or more substituents are selected from the group consisting of alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro, and -(R₇)_nNR₈R₉, wherein R₇, R₈, R₉ and *n* are as defined above, and

R₂ and R₃ are:

- a) independently selected from the group consisting of H, alkyl, aralkyl optionally substituted aryl, optionally substituted heteroaryl and optionally substituted, saturated or unsaturated, 5- or 6-

membered, homocyclic or heterocyclic rings wherein the optional substituent may be selected from the group consisting of H, alkyl, alkoxy, and halo;

or

- b) joined together to form a 3, 4, 5, 6 or 7 member spirocyclic ring, and

Ar₁ is aryl and;

Ar₁ is optionally substituted with one or more substituents R_b; wherein R_b is selected from the group consisting of: alkyl, alkoxy, halo, haloalkyl, nitro, -(R₇)_nNR₈R₉, alkanoyl, aryl, heteroaryl, -O(CH₂)_mNR₁₀R₁₁ and -SO₂-NR₁₀R₁₁ (wherein R₇ is selected from alkyl, alkoxy; and oxyalkyl, R₈ and R₉ can be independently selected from H, and alkyl, or R₈ and R₉ can join together such that NR₈R₉ form a 5 or 6- member heterocyclic ring, and *n* is selected from 0, 1, 2 and 3) and the groups R₁₀ and R₁₁ can be independently selected from H, or alkyl, or groups R₁₀ and R₁₁ can join together such that NR₁₀ R₁₁ form a 5 or 6-member ring, and *m* is selected from 1, 2, 3, 4 and 5);

wherein the substituent(s) R_b are optionally further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro and -(R₇)_nNR₈R₉ (wherein R₇, R₈, R₉ and *n* are as described above).

wherein when Ar₁ is phenyl then

- a) Ar₁ has a substituent R_b at the 2-position wherein the substituent is selected from the group consisting of nitro, haloalkyl, cyano, -C(O)R₁₂ -C(O)OR₁₂, -C(O)NR₁₂R₁₂, -S(O)R₁₂, -S(O)₂R₁₂, and -S(O)₂NR₁₂R₁₃ (wherein R₁₂ and R₁₃ are independently selected from H and alkyl)

or

b) Ar₁ has an alkanoyl substituent at the 4-position,

and a salt solvate or hydrate thereof.

2. A compound of claim 1 wherein Ar₁ is selected from the group consisting of phenyl and naphthyl.
3. A compound of claim 2 wherein Ar₁ is naphthyl.
4. A compound of claim 2 wherein Ar₁ is 4-acetylphenyl.
5. A compound of claim 2 wherein Ar₁ is phenyl, and there is a substituent R_b at the 2-position and R_b is selected from the group consisting of nitro, trifluoromethyl and -SO₂-NR₁₀R₁₁.
6. A compound of claim 5 wherein the substituent R_b at the 2-position is nitro.
7. A compound of claim 5 with a second substituent R_b at the 4-position selected from the group consisting of: methoxy; ethoxy; propoxy; -O(CH₂)_mNR₁₀R₁₁ and acetyl.
8. A compound of claim 7 wherein Ar₁ is 2-nitro-4-methoxyphenyl.
9. A compound of claim 1 wherein R₁ is selected from the group consisting of: phenyl; naphthyl; tetrahydronaphthyl; and pyridyl.
10. A compound of claim 9 wherein R₁ is pyridyl.
11. A compound of claim 9 wherein R₁ is naphthyl or tetrahydronaphthyl.
12. A compound of claim 9 wherein R₁ is phenyl.
13. A compound of claim 12 wherein R₁ is substituted with one or more substituents R_a, wherein R_a is selected from the group consisting of: alkyl; alkoxy; halo; cyano; thioalkyl; nitro; alkanoyl; haloalkyl; acetyl; piperazinyl.
14. A compound of claim 13 wherein the substituent(s) R_a are independently selected from the group consisting of: methyl; ethyl; isopropyl; chloro; fluoro; trifluoromethyl; thiomethyl; cyano; nitro; methoxy and piperazinyl.
15. A compound of claim 14 wherein there is one substituent R_a.

16. A compound of claim 15 wherein the substituent R_a is located at the 2-position of the phenyl ring R_1 .
17. A compound of claim 16 wherein R_a is methyl.
18. A compound of claim 14 wherein there are two substituents R_a .
19. A compound of claim 18 wherein the two substituents R_a are located at the 2-position and the 6-position.
20. A compound of claim 19 wherein one of the substituents R_a is methyl, and the second substituent R_a is selected from the group consisting of: methyl, and ethyl.
21. A compound of claim 20 wherein the second substituent R_a is methyl.
22. A compound as defined in claim 1 wherein R_2 and R_3 are independently selected from H, alkyl, aralkyl, and optionally substituted, saturated or unsaturated, 5 or 6-member homocyclic or heterocyclic rings; or R_2 and R_3 are joined together to form a 3, 5 or 6 member spirocyclic ring.
23. A compound as described in claim 22 wherein R_2 and R_3 are selected independently from H, methyl, isopropyl, t-Butyl, sec-Butyl, cyclohexyl, phenyl, benzyl, 3-thiophene.
24. A compound as described in claim 22 wherein R_2 and R_3 join together to form a 3, 5, or 6-member spirocyclic ring.
25. A compound from claim 1 selected from the group consisting of:
N-(2-methylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide **(E4.3)**;
N-(2,6-dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide **(E33.6)**;
N-(2-methylphenyl)-2-[3-(2-nitrophenyl)-thioureido]-2-phenyl acetamide **(E4.2)**
N-(2-methylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)-thioureido]-2-phenyl acetamide **(E4.4)**;
N-(2,6-dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)-thioureido]-2-phenyl acetamide **(E33.7)**;
N-(2,6-dimethylphenyl)-2-[3-(4-N,N-dimethylaminoethoxy-2-trifluoromethylphenyl)-thioureido]-2-phenyl acetamide **(E33.8)**;

N-(2-isopropyl-6-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (**E28.1**);
N-(2-chloro-6-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (**E29.1**);
N-(2,6-dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-4-methylpentanamide (**E51.3**);
N-(2,6-dimethylphenyl)-2-[3-(4-(2-N,N-dimethylamino)ethoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (**E33.4**);
(*R*)-N-(2,6-dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-4-methylpentanamide (**E51.1***);
N-(2,6-dimethylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (**E33.1**);
N-(2,6-dimethylphenyl)-2-[3-(2-N,N-dimethylsulphonamidophenyl)-thioureido]-2-phenyl acetamide (**E33.2**);
N-(2,6-dimethylphenyl)-2-[3-(2-N-methylpiperizinylsulphonamidophenyl)-thioureido]-2-phenyl acetamide (**E33.3**);
and N-(2,6-dimethylphenyl)-2-[3-(4-(2-N,N-dimethylamino)sulphonamide-2-nitrothioureido]-2-phenyl acetamide (**E33.5**).

26. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
27. A method for treating a patient having a medical condition for which a glycine transport inhibitor is indicated, comprising the step of administering to a patient a pharmaceutical composition as described in claim 26.
28. A method according to claim 27 wherein the medical condition is pain or spasticity.